people reached through BMS'
health equity grants (2020-2023)
2023 ESG Report - Bristol Myers Squibb
“BMS has long been committed to corporate responsibility, and our refined ESG strategy is the result of the commitment by the entire organization to advance our sustainability. Together, we are building a legacy that combines our rich history with a future of innovation, responsibility and growth.”
Christopher S. Boerner, Ph.D.
Board Chair and CEO at Bristol Myers Squibb
ENVIRONMENTAL, SOCIAL AND GOVERNANCE
As of July 2024, BMS' third party verified (limited assurance) 2023 environmental metrics are available. Click here to learn more about our ESG strategy, commitments and progress against our goals.
Our ESG strategy
Our ESG strategy is interconnected to our company's core strategy by focusing on three core pillars:
ESG can support long-term value creation, and, when needed, we will adapt our business model so we are best positioned to address the shared challenges that society faces on environmental, social and governance issues — and to do so with a science-led, innovation-focused approach that is rooted in health equity.
“We take our obligation to build and maintain trust with our stakeholders very seriously. Our ESG commitments are our compact with society — we hold ourselves accountable to these standards, and to making a meaningful and measurable impact in the communities where we live and work.”
Cari Gallman
Executive Vice President of Corporate Affairs at Bristol Myers Squibb
Recent ESG highlights
emerging market brands
(EMBs) filed
Low- and middle-income countries
(LMICs) have potential direct import
(DI) access for 12 BMS medicines
of clinical trial sites1 were located in
highly diverse area's of the U.S.
racially diverse clinical trial participants,
exceeding target goal of 20%
patients reached globally2
References
1Defined as 30%+ non-white;
2 Excluding established brands (Baraclude®, Abraxane®, Vidaza®, Reyataz® and Nulojix®)
